#USA #San Francisco #Immorta Bio #SenoVax #StemCellRevivify

Immorta Bio: Pioneering Longevity Solutions

In a remarkable breakthrough, Immorta Bio Inc., a cutting-edge scientific company focused on longevity, has unveiled findings that could reshape our understanding of aging. Their innovative combination therapy, which pairs SenoVax™, a first-in-class senolytic immunotherapy, with personalized mesenchymal stem cells (pMSCs) derived from the StemCellRevivify™ platform, has demonstrated the ability to double the lifespan of mice in validated aging models.

New Research Findings

This groundbreaking research will be presented by Dr. Boris Reznik, the company’s Chairman and CEO, at the Biotech Showcase 2026 in San Francisco during the J.P. Morgan Healthcare Conference Week on January 12. The results of this study represent a significant advancement in longevity science, showcasing the efficacy of the combination therapy over monotherapy approaches.

In experiments using two validated aging models—carbon tetrachloride (CCl₄)-induced liver injury and doxorubicin-induced systemic senescence—Immorta Bio's treatment showcased impressive results:

• - A marked reduction in senescence-associated secretory phenotype (SASP) markers, including IL-11, YKL-40, IL-6, and IL-23R.
• - A strong upregulation of regenerative and rejuvenation biomarkers such as Klotho, FGF-2, neo-VEGF, and GDF-11.
• - Significant improvements in liver function, shown by reduced AST and ALT levels.
• - Enhancements in physical performance, particularly noted via enhanced climbing abilities which indicate preserved strength and vitality.
• - The most astonishing outcome was the doubling of lifespan in the doxorubicin model, demonstrating synergistic survival benefits that far surpassed either therapy alone.

The Science Behind the Breakthrough

Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, emphasized that this breakthrough supports a new paradigm in longevity medicine. He noted, "Senescent cells and their inflammatory secretions actively inhibit tissue regeneration. By first eliminating this barrier with our first-in-class senolytic immunotherapy SenoVax™, we enable breakthrough personalized regenerative stem cells to restore function in ways not achievable with either approach alone."

Immorta Bio’s dual-platform strategy addresses two core hallmarks of aging: the accumulation of senescent cells targeted by SenoVax™, and the loss of regenerative capacity restored by StemCellRevivify™. Both platforms are advancing towards clinical development, with SenoVax™ currently undergoing FDA review.

Looking to the Future

As Immorta Bio continues to carve its path in the field of longevity and regenerative medicine, it opens up invitations for investors, strategic partners, and media representatives to engage with them at the upcoming Biotech Showcase 2026. The company aims to revolutionize how we approach aging and disease, challenging existing perceptions and providing tangible solutions.

In summary, Immorta Bio’s recent findings not only highlight the profound possibilities of longevity science but also put an emphasis on the importance of targeting the mechanisms of aging at a cellular level. This could pave the way for novel interventions that might one day help extend human lifespan and healthspan—an aspiration long pursued in biomedical research.

With innovative therapies like SenoVax™ and the StemCellRevivify™ platform in development, the future of aging science appears promising, as researchers strive to combat diseases of aging and ultimately treat aging itself as a disease. Stay tuned for more updates from Immorta Bio as they continue their pioneering work in this exciting field!